Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy
Open Access
- 25 August 2015
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 446
Abstract
The purpose of this study was to investigate whether the overall treatment time and completion rates of chemotherapy were predictive factors for the survival rates in patients with squamous cell carcinoma of the head and neck (SCCHN) who were treated with concurrent chemoradiotherapy (CCRT) using hyperfractionated radiotherapy (RT) and daily carboplatin. The number of intermission days of RT were as follows; 0 (n = 37), 1–5 (n = 8), 6–10 (n = 12) and ≥11 (n = 12), and the days of RT without carboplatin; 0 (n = 27), 1–5 (n = 13), 6–10 (n = 13) and ≥7 (n = 16). The overall treatment time (≤48 vs ≥49 days) was a significant prognostic factor for the local control, disease-free survival and overall survival rates. The completion rate of chemotherapy, as the number of days of RT without carboplatin, was not a significant factor affecting any of the survival rates. In discussion, the strengths of the present study contain that all the patients were treated with 72 Gy delivered as 1.2 Gy twice daily, and received concurrent chemotherapy comprising daily carboplatin as a radio-sensitizer. Based on the results, the completion rate of chemotherapy may have a lower impact on the local control rate in comparison with the overall treatment time. We believe that when a treatment interruption is needed because of the acute toxicities, hyperfractionated RT should be resumed as soon as possible independently while continuing the break of daily carboplatin. The overall treatment time influenced the clinical outcomes in SCCHN patients treated with hyperfractionated CCRT using carboplatin, while the impact of the completion rates of daily carboplatin was limited. Sixty-nine consecutive patients with SCCHN were initially treated with definitive CCRT and were retrospectively analyzed. All 69 patients were treated with CCRT using hyperfractionated RT of 72 Gy in 60 fractions and daily carboplatin (25 mg/m2). The patients treated with other chemotherapeutic regimens or induction chemotherapy were excluded. On the intermission days of the RT, carboplatin was not prescribed. After the intermission, CCRT using RT plus daily carboplatin or RT alone was resumed.Keywords
This publication has 21 references indexed in Scilit:
- Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experienceHead & Neck Oncology, 2009
- Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trialEuropean Journal of Cancer, 2007
- Accelerated Radiotherapy and Larynx Preservation in Favorable-risk Patients with T2 or Worse Hypopharyngeal CancerJapanese Journal of Clinical Oncology, 2007
- The Additional Value of Chemotherapy to Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Meta-Analysis of the Published LiteratureJournal of Clinical Oncology, 2004
- How fast is repopulation of tumor cells during the treatment gap?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck CancerNew England Journal of Medicine, 1998
- Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancerRadiotherapy and Oncology, 1996
- Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local controlRadiotherapy and Oncology, 1996
- Local control of T3 carcinomas after accelerated fractionation: A look at the “Gap”International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapyRadiotherapy and Oncology, 1992